About Viral Genetics, Inc.

Viral Genetics, Inc. is a biotechnology company researching new treatments and methods of detection for HIV/AIDS, Lyme Disease, staph and strep, cancer and certain other autoimmune and infectious diseases. Two approaches based on patent rights licensed from the University of Colorado and University of Vermont form the basis of our research: Targeted Peptides Therapies (TPT) and Metabolic Disruption Technology (MDT). TPTs are custom-designed protein fragment that work to modify certain immune system reactions that we believe cause or worsen some diseases. The TPT compounds we are studying represent in some sense the second generation of our earlier thymus nuclear protein or “TNP” therapy. MDT encompasses a way to change how some types of cells use fat and sugar/carbohydrates for energy. By manipulating metabolic processes, we believe we can cause some harmful cells – including drug-resistant cancer cells – to die. The same MDT approach has also recently been discovered to have potential in encouraging the production of oils from algae and other plants. As a result of this, we established a subsidiary called VG Energy to develop these applications.

Our management team and advisors include two Nobel Laureates, Dr. Luc Montagnier and Dr. Baruch Blumberg, leading researchers, business and intellectual property veterans and drug development experts.